REGiMMUNE

#Autoimmune disease #Cell therapy #Immuno-oncology #Kiji Therapeutics #Mergers and acquisitions #Monoclonal antibodies #REGiMMUNE #Stem cells

REGiMMUNE and Kiji Therapeutics announce intention to merge

Biopharmaceutical company REGiMMUNE and biotech Kiji Therapeutics have announced an intention to merge, creating a global Treg specialist that will target multiple indications. The new company, called REGiMMUNE/Kiji TX will combine the complimentary portfolio of platforms and therapies to create an international Treg biotech. Read More

#Business & Investment #News